Chronic lymphocytic leukemia (CLL), the most frequent form of leukemia in Western countries, is characterized by the clonal proliferation and accumulation of neoplastic B lymphocytes in the blood,bone marrow,lymph nodes and spleen.During the past decades,important advances have been made in the understanding of the biology,pathology,diagnosis and treatment of CLL.In the 53rd ASH annual meeting,lots of new discoveries about the biology, prognosis, and treatment of CLL were introduced which lead us to further understand CLL and may provide more or better treatments for CLL patients.

Hodgkin's lymphoma(HL)is a highly curable malignancy for most patients during the recent decades.Frontline treatment is generally ABVD alone or in combination with other chemotherapy regimens or radiation. To achieve a higher control of disease, ABVD chemotherapy has been challenged by more intensive treatments, such as Stanford V and BEACOPP regimen. In the 53rd ASH annual meeting,ABVD is still widely accepted as standard regimen for HL, even in elderly people or patients with HIV infection. Relapsed or refractory HL is a challenging problem for clinician, and high dose chemotherapy followed by autologous stem cell transplantation(HDC/ASCT)is the preferred treatment for chemoresistant patients.Many novel treatment strategies were explored for these patients.Positron emission tomography (PET) scanning provides important prognostic information in patients with HL receiving chemotherapy or pre/posttransplant,but the utility of long term surveillance radiological studies is not recommended in the meeting.

Early stage Hodgkin' s lymphoma (HL) is highly curable with abbreviated chemotherapy plus involved-filed radiotherapy or chemotherapy alone,but the role of radiation remains the subject of debate and disagreement.The management of recurrent or refractory HL remains challenging with limited effective treatments except high dose therapy with autologous stem cell transplantation.Emerging new safe and effective drugs such as brentuximab vedotin might promisingly improve the outcome of these patients in the future.The interim positron emission tomography (PET-i) scan has important prognostic value in patients with early and advanced stage HL,especially PET scan after 2 cycles.However,the PET-i guided treatment decisions are not currently recommended outside clinical trials.

Follicular lymphoma (FL) is a kind of indolent Non-Hodgkin lymphoma (NHL),which stems from follicle germinal center.A lot of research reported the latest development about treatment of FL in the 56th American Society of Hematology (ASH) annual meeting.Effect of radiotherapy for patients at low stage was determined,while the outcomes of clinical trials in which monoclonal antibody (GA101) in combination with chemotherapy for the advanced stage FL were exciting.In rituximab era,relapsed/refractory FL patients who receive stem cell transplantation could acquire preferable remissions.Several novel drugs (inhibitor of BTK or PI3K) for relapsed/refractory FL played a role of guidepost with the progression of corresponding trials.

Diffuse large B cell lymphoma (DLBCL) is one of the most common non-Hodgkin lymphoma (NHL).Since the appearance of rituximab,the most common first-line therapy is rituximab in combination with chemotherapy.About 70 percent of patients could achieve complete remission (CR) and be cured finally.But one third of patients could not reach CR after frontline treatment or relapse early,especially the elder patients or high risk ones.In the 56th American Society of Hematology (ASH) annual meeting,a plenty of treatments focusing on these patients brought encouraging results,which makes it possible to further improve the CR rate.The progresses in relapse/refractory,high risk and special site DLBCL will be summarized in this paper based on the reports in the 56th ASH annual meeting.

Waldenstrom macroglobulinemia (WM) is a malignant B-cell lymphoproliferative disorder, which still remains incurable. Reports on the latest research progress of WM were presented in the 58th American Society of Hematology (ASH) Annual Meeting, covering the theoretical and clinical researches of this disease. In basic research, mechanism of ibrutinib resistance has been further explored. The application of modern technologies, such as next-generation sequencing, has promoted the pathogenesis and prognosis of WM. In clinical research, retrospective analyses of traditional treatment provide new theoretical foundation in the choice of regimen, while clinical trials on new drugs including BGB-3111 and oprozomib may improve the therapy. The research advances in WM will be summarized in this paper.

Hodgkin lymphoma (HL) is a highly curable malignancy for most patients. Frontline treatment is generally ABVD alone or combination with other chemotherapy regimens or radiation. However, the treatment of relapsed refractory HL (RR HL) remains a major challenge for clinicians. High dose chemotherapy followed by autologous stem cell transplantation is the preferred treatment for chemoresistant patients. In addition, the combination of brentuximab vedotin (BV) with programmed cell death receptor 1 monoclonal antibody nivolumab, BV combined with ICE (ifosfamide, carboplatin, etoposide), panobinotast in combination with ICE and many other new drugs are in clinical trials and research. The latest progress in treatment of HL is reported in depth in the 58th American Society of Hematology Annual Meeting.

Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma with highly heterogeneous clinical course. How to recognize patients with high risk is coming into the focus of the 57th American Society of Hematology (ASH) annual meeting. The International Prognostic Index (IPI) score as a classic prognostic system is challenged by variety of new prognosis systems. The tumor microenvironment plays an important role in progression of lymphoma, and its prognostic value draw much more attention. The value of PET-CT for prognosis of DLBCL has also been affirmed in this meeting.

Follicular lymphoma (FL) is a kind of indolent non-Hodgkin lymphoma (iNHL), which origins from follicle germinal center. Multiple researches reported the latest development about treatment of FL in the 58th American Society of Hematology (ASH) Annual Meeting. The outcomes of clinical trials in which GAl01 combined with chemotherapy and bendamustine in combination with 90Y-ibritumomab tiuxetan for the advanced stage FL were exciting. Relapsed/refractory FL patients who receive tandem autologous followed by nonmyeloablative allogeneic transplantation could acquire preferable remissions. With the emerging of novel drugs including inhibitor of bcl-2 or PI3K and antibody drug conjugate, more and more improvements of efficacy and remission were made in the treatment of relapsed/refractory FL therapy and remission.

Positron emission tomography-computed tomography (PET-CT) with both anatomic and functional information is now widely utilized for most lymphoma subtypes,among which,the pretreatment staging and response assessment of PET-CT in Hodgkin lymphoma (HL) and diffuse large B-cell lymphoma (DLBCL)have been well documented.Multiple clinical trials are ongoing using PET-CT for therapy monitoring.Additionally,factors interpreting interim PET (PET-i) like visual analysis using Deauville 5-PS,metabolic tumor volume at baseline (MTV0),and △ SUVmaxPET0-i show different prognostic values.However,the management of PET-CT in lymphoma is still elusive,further trials remain to be done to get evidences for the use of PET-CT in guiding therapeutic decisions.